Name | Number of supported studies | Average coverage | |
---|---|---|---|
pericyte | 26 studies | 36% ± 14% | |
smooth muscle cell | 17 studies | 25% ± 8% | |
glutamatergic neuron | 10 studies | 41% ± 24% | |
platelet | 8 studies | 30% ± 13% | |
fibroblast | 6 studies | 27% ± 13% | |
endothelial cell | 5 studies | 28% ± 6% | |
GABAergic neuron | 5 studies | 48% ± 15% | |
myofibroblast cell | 4 studies | 30% ± 14% | |
connective tissue cell | 4 studies | 24% ± 7% | |
interneuron | 4 studies | 45% ± 20% | |
hematopoietic stem cell | 4 studies | 30% ± 15% | |
neuron | 3 studies | 31% ± 7% | |
OFF-bipolar cell | 3 studies | 35% ± 9% | |
rod bipolar cell | 3 studies | 22% ± 4% | |
megakaryocyte | 3 studies | 54% ± 21% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 38% ± 20% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 38% ± 20% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 4389.79 | 2613 / 2642 | 98% | 26.09 | 688 / 705 |
prostate | 96% | 1480.84 | 236 / 245 | 96% | 20.97 | 484 / 502 |
breast | 98% | 1556.55 | 452 / 459 | 94% | 15.44 | 1051 / 1118 |
lung | 100% | 2522.60 | 577 / 578 | 92% | 16.53 | 1067 / 1155 |
thymus | 97% | 1177.31 | 635 / 653 | 90% | 14.22 | 547 / 605 |
kidney | 93% | 1177.27 | 83 / 89 | 93% | 48.73 | 839 / 901 |
ovary | 62% | 725.09 | 111 / 180 | 94% | 27.01 | 404 / 430 |
esophagus | 76% | 2257.68 | 1096 / 1445 | 79% | 13.60 | 145 / 183 |
pancreas | 61% | 481.89 | 200 / 328 | 93% | 18.47 | 165 / 178 |
intestine | 87% | 2964.70 | 839 / 966 | 66% | 9.26 | 346 / 527 |
uterus | 99% | 2132.84 | 168 / 170 | 53% | 8.13 | 244 / 459 |
stomach | 69% | 1778.08 | 248 / 359 | 80% | 14.87 | 230 / 286 |
bladder | 76% | 884.95 | 16 / 21 | 58% | 6.55 | 293 / 504 |
blood vessel | 100% | 3012.64 | 1333 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 2012.15 | 1194 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 1394.35 | 843 / 861 | 0% | 0 | 0 / 0 |
spleen | 98% | 1005.27 | 235 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 16% | 109.66 | 42 / 258 | 72% | 27.59 | 165 / 230 |
skin | 37% | 282.28 | 663 / 1809 | 50% | 6.56 | 234 / 472 |
tonsil | 0% | 0 | 0 / 0 | 76% | 15.96 | 34 / 45 |
liver | 32% | 200.79 | 72 / 226 | 39% | 5.68 | 160 / 406 |
lymph node | 0% | 0 | 0 / 0 | 66% | 7.29 | 19 / 29 |
muscle | 48% | 331.53 | 383 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 15% | 494.84 | 137 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 6% | 0.62 | 5 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019934 | Biological process | cGMP-mediated signaling |
GO_0006182 | Biological process | cGMP biosynthetic process |
GO_0038060 | Biological process | nitric oxide-cGMP-mediated signaling |
GO_0071732 | Biological process | cellular response to nitric oxide |
GO_0007263 | Biological process | nitric oxide mediated signal transduction |
GO_0008015 | Biological process | blood circulation |
GO_0070482 | Biological process | response to oxygen levels |
GO_0099555 | Biological process | trans-synaptic signaling by nitric oxide, modulating synaptic transmission |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005829 | Cellular component | cytosol |
GO_0008074 | Cellular component | guanylate cyclase complex, soluble |
GO_0098831 | Cellular component | presynaptic active zone cytoplasmic component |
GO_0004016 | Molecular function | adenylate cyclase activity |
GO_0038023 | Molecular function | signaling receptor activity |
GO_0051879 | Molecular function | Hsp90 protein binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0005525 | Molecular function | GTP binding |
GO_0047805 | Molecular function | cytidylate cyclase activity |
GO_0020037 | Molecular function | heme binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004383 | Molecular function | guanylate cyclase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | GUCY1B1 |
Protein name | Guanylate cyclase soluble subunit beta-1 (EC 4.6.1.2) (Guanylate cyclase soluble subunit beta-3) (Soluble guanylate cyclase small subunit) Guanylate cyclase soluble subunit beta-1 (GCS-beta-1) (EC 4.6.1.2) (Guanylate cyclase soluble subunit beta-3) (GCS-beta-3) (Soluble guanylate cyclase small subunit) |
Synonyms | GUC1B3 GUCSB3 hCG_28052 GUCY1B3 |
Description | FUNCTION: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. . FUNCTION: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. . FUNCTION: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. . FUNCTION: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. . FUNCTION: Mediates responses to nitric oxide (NO) by catalyzing the biosynthesis of the signaling molecule cGMP. . |
Accessions | ENST00000505764.5 [Q02153-3] ENST00000505154.5 ENST00000503520.5 [Q02153-2] B7Z685 ENST00000513437.1 ENST00000502959.5 ENST00000652626.1 A0A494C1B9 Q02153 ENST00000264424.13 [Q02153-1] E9PCN2 ENST00000507146.5 D6RC99 |